JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
[Bibliometric analysis of bacterial quantitative proteomics in English literatures].
Zhonghua Nei Ke Za Zhi
PUBLISHED: 09-30-2014
Show Abstract
Hide Abstract
To analyze the worldwide advances on bacterial quantitative proteomics over the past fifteen years with bibliometric approach.
Related JoVE Video
Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
World J. Microbiol. Biotechnol.
PUBLISHED: 08-18-2014
Show Abstract
Hide Abstract
In comparison with ciprofloxacin, levofloxacin and moxifloxacin, antimicrobial activity of nemonoxacin against ciprofloxacin-susceptible/-resistant methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) was determined with the availability to select resistant mutants evaluated. Minimum inhibitory concentrations and mutant prevention concentrations of quinolones were determined by agar dilution method, that concentrated bacterial cells were spread onto Mueller-Hinton agar plates containing antibacterials at different concentrations. Selection index (SI) was calculated. Minimum inhibitory concentration and mutant prevention concentration of nemonoxacin were 0.063 and 0.25 ?g/mL for ciprofloxacin-susceptible MSSA and those were 0.5 and 4.0 ?g/mL for ciprofloxacin-resistant MSSA, lower than observations of three fluoroquinolones distinctly. SI of nemonoxacin and moxifloxacin were similar, with narrower mutant selective window than levofloxacin and ciprofloxacin. Minimum inhibitory concentration and mutant prevention concentration of nemonoxacin were 0.25 and 2.0 ?g/mL for ciprofloxacin-susceptible MRSA, which were 0.5 and 16.0 ?g/mL for ciprofloxacin-resistant MRSA. Values were lower than those determined from fluoroquinolones. Nemonoxacin presents good antimicrobial activity against clinical isolates of S. aureus, especially for ciprofloxacin-resistant strains. But stepwise mutant accumulation of ciprofloxacin-resistant MRSA can be hardly inhibited by nemonoxacin with pharmacokinetic parameters considered.
Related JoVE Video
In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
J Chemother
PUBLISHED: 07-29-2014
Show Abstract
Hide Abstract
Over the last decade, multidrug-resistant Acinetobacter baumannii (MDRAB) has emerged as one of the most problematic nosocomial pathogens. Empirical combination therapy has become a common practice to treat patients infected with MDRAB. In vitro interactions of tigecycline with cefoperazone-sulbactam were assessed in 72 MDRAB isolates. Minimum inhibitory concentrations (MICs) were determined by broth microdilution method. Antibiotic interactions were determined by chequerboard and time-kill assays. Chequerboard analysis showed 29ยท2% synergy and no antagonistic interactions. Time-kill assays confirmed the synergistic interaction between two agents for three of four selected extensively drug-resistant A. baumannii (XDRAB) isolates. No antagonism was revealed by time-kill assays. Moreover, tigecycline in combination with cefoperazone-sulbactam appeared to be more effective than tigecycline in combination with sulbactam against XDRAB. In conclusion, in vitro synergistic activities of tigecycline in combination with cefoperazone-sulbactam against MDRAB were demonstrated, suggesting a superior treatment option against MDRAB.
Related JoVE Video
Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii.
Rev. Soc. Bras. Med. Trop.
PUBLISHED: 04-12-2014
Show Abstract
Hide Abstract
Acinetobacter baumannii has attained an alarming level of resistance to antibacterial drugs. Clinicians are now considering the use of older agents or unorthodox combinations of licensed drugs against multidrug-resistant strains to bridge the current treatment gap. We investigated the in vitro activities of combination treatments that included colistin with vancomycin, norvancomycin or linezolid against multidrug-resistant Acinetobacter baumannii.
Related JoVE Video
Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Chin. Med. J.
PUBLISHED: 03-14-2014
Show Abstract
Hide Abstract
Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. The aim of this study was to compare the efficacy and safety of ertapenem with ceftriaxone.
Related JoVE Video
Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries.
J Thorac Dis
PUBLISHED: 01-22-2014
Show Abstract
Hide Abstract
National treatment/diagnosis guidelines for lower respiratory tract infections (LRTIs) are generally based on local epidemiological data. Etiology and drug-resistance patterns could differ between China and European/American countries, and simply following their respective guidelines might cause problems in clinical practice. Therefore, we need to summarize the microbiology and clinical manifestations of LRTIs in China and develop our own guidelines.
Related JoVE Video
Sustained improvement of gas exchange and lung mechanics by vaporized perfluorocarbon inhalation in piglet acute lung injury model.
Clin Respir J
PUBLISHED: 08-27-2013
Show Abstract
Hide Abstract
New methods for perfluorocarbon (PFC) application have been proposed which include aerosolization and vaporization. However, the experimental documentation of efficacy of vaporization of PFC in the treatment of acute respiratory distress syndrome (ARDS) is still lacking.
Related JoVE Video
In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
J. Antibiot.
PUBLISHED: 07-20-2011
Show Abstract
Hide Abstract
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). A total of 87 clinical isolates of MRSA collected from three Chinese hospitals were included in the study. The checkerboard method with determination of the fractional IC index (FICI) was used to determine whether antibiotic combinations act synergistically against these isolates. The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. The results demonstrated the following interactions: 76 isolates (87.4%) showed synergistic interactions (FICI?0.5) and 11 isolates (12.6%) showed indifferent interactions (0.5
Related JoVE Video
Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.
J. Antimicrob. Chemother.
PUBLISHED: 03-02-2011
Show Abstract
Hide Abstract
To evaluate the efficacy and safety of macrolides in cystic fibrosis (CF).
Related JoVE Video
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
Antimicrob. Agents Chemother.
PUBLISHED: 12-20-2010
Show Abstract
Hide Abstract
The aim of this study was to compare the efficacy and safety of tigecycline, a newly developed glycylcycline antibiotic, with those of empirical antibiotic regimens which have been reported to possess good efficacy for complicated skin and skin structure infections (cSSSIs), complicated intra-abdominal infections (cIAIs), community-acquired pneumonia (CAP), and other infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). A meta-analysis of randomized controlled trials (RCTs) identified in PubMed, the Cochrane Library, and Embase was performed. Eight RCTs involving 4,651 patients were included in the meta-analysis. Compared with therapy with empirical antibiotic regimens, tigecycline monotherapy was associated with similar clinical treatment success rates (for the clinically evaluable [CE] population, odds ratio [OR] = 0.92, 95% confidence interval [CI] = 0.76 to 1.12, P = 0.42; for the clinical modified intent-to-treat [c-mITT] population, OR = 0.86, 95% CI = 0.74 to 1.01, P = 0.06) and similar microbiological treatment success rates (for the microbiologically evaluable [ME] population, OR = 0.86, 95% CI = 0.69 to 1.07, P = 0.19). The incidence of adverse events in the tigecycline group was significantly higher than that in the other therapy groups with a statistical margin (for the modified intent-to-treat [mITT] population, OR = 1.33, 95% CI = 1.17 to 1.52, P < 0.0001), especially in the digestive system (mITT population, OR = 2.41, 95% CI = 1.67 to 3.46, P < 0.00001). No difference regarding all-cause mortality and drug-related mortality between tigecycline and the other regimens was found, although numerically higher mortality was found in the tigecycline group. This meta-analysis provides evidence that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE. However, because of the high risk of mortality, AEs, and emergence of resistant isolates, prudence with the clinical use of tigecycline monotherapy in infections is required.
Related JoVE Video
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
Antimicrob. Agents Chemother.
PUBLISHED: 06-28-2010
Show Abstract
Hide Abstract
The antimicrobial activities of colistin and other antibiotics against clinical Acinetobacter baumannii and the mutant prevention concentration (MPC) of colistin against multidrug-resistant A. baumannii were studied. All 70 stains tested were sensitive to colistin. The MPC range of colistin against 30 multidrug-resistant A. baumannii stains was approximately 32 to >128 microg/ml, and the MPC at which 90% of the isolates tested were prevented (MPC(90)) exceeded 128 microg/ml, which was much higher than the plasma concentration of colistin at the current recommended dosage. So, combination therapy for colistin treatment of A. baumannii would be prudent to slow the emergence of resistance.
Related JoVE Video
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.
BMC Microbiol.
PUBLISHED: 02-24-2010
Show Abstract
Hide Abstract
Pseudomonas aeruginosa is a common pathogen in chronic respiratory tract infections. It typically makes a biofilm, which makes treatment of these infections difficult. In this study, we investigated the inhibitory effects of N-acetylcysteine (NAC) on biofilms produced by P. aeruginosa.
Related JoVE Video
Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population.
BMC Infect. Dis.
PUBLISHED: 03-18-2009
Show Abstract
Hide Abstract
Knowledge of predominant microbial patterns in community-acquired pneumonia (CAP) constitutes the basis for initial decisions about empirical antimicrobial treatment, so a prospective study was performed during 2003-2004 among CAP of adult Chinese urban populations.
Related JoVE Video
Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.
J. Antibiot.
Show Abstract
Hide Abstract
Linezolid is an important therapeutic option for infections from multi-drug resistant Gram-positive pathogens. However, prolonged linezolid treatment (>14 days) is considered to increase the risk of hematological adverse events. We aimed to evaluate the hematological safety profile of an i.v. single dose of linezolid in healthy volunteers of different body weight. We conducted a phase I clinical trial involving 20 healthy male Chinese volunteers that received an i.v. single dose of linezolid (600?mg). The study participants were assigned to two groups: low-weight (LW) group: 50?kg
Related JoVE Video
simple hit counter

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.